Light-activated metal complex that cleaves tumor cell DNA
This technology creates specially engineered molecules that combine two functional components: a platinum-based unit that physically attaches to DNA, and a light-absorbing unit that, when illuminated, generates toxic oxygen radicals right at the DNA binding site. The result is a molecule that first finds and grips DNA, then—upon light activation—cuts it by producing reactive oxygen species in its immediate vicinity. This dual-action approach makes the cleavage highly localized and controllable, since damage only occurs when light is applied. The underlying chemistry is a class of multi-component metallic complexes synthesized with specific bridging ligands to hold the functional units together.
What you could build
A photodynamic therapy (PDT) drug candidate—a light-activated chemotherapeutic agent that could be administered to patients and then triggered by external light to destroy tumor DNA. Oncology drug developers and photodynamic therapy platform companies would be the primary buyers or licensees.
Who in Virginia should care
Biotech and pharmaceutical companies in the Virginia/DC/Maryland corridor, as well as oncology research programs at Virginia academic medical centers, would be natural partners or licensees.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Karen J. Brewer, Brenda Winkel
- Granted
- April 3, 2012
- Status
- Granted patent
- Patent number
- 8148360
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.